MSI is a selective, PTP1B inhibitor which protects rodents from diet-induced obesity (DIO) and for that reason is now being tested in clinical trials as an anti-diabetic agent for humans (in accordance with ClinicalTrials.gov, 4 studies have been performed). Here, PTPN1 is linked to Obesity.